• Predicting When Alzheimer’s Symptoms Will Emerge

    Bio-IT World | The Foundation for the National Institutes of Health (FNIH), Washington University in St. Louis, the University of California San Francisco, the University of Wisconsin-Madison, and more have published the results of a study in Nature Medicine that determined a blood-based biomarker model that estimates not only the likelihood of Alzheimer’s disease but also when symptoms are likely to emerge.

    Feb 24, 2026
  • Welcome to the Next Frontier in Drug Discovery: The Surfaceome

    Bio-IT World | The scientific community has made tremendous progress in the ability to identify and predict protein targets, advancing from bulk cellular analysis approaches to technologies with resolutions that now approach subcellular. Despite these achievements, fundamental questions in drug discovery remain difficult to answer: has the ideal protein target been identified, and is it easily accessible to intervention to accelerate the development pipeline and reduce candidate attrition?

    Feb 20, 2026
  • Deloitte Survey Reveals Sharp Divide for This Year’s Outlook

    Bio-IT World | During the Clinical Trial Venture, Innovation, and Partnering event at this year’s SCOPE, Deloitte Consulting’s 2026 Life Sciences Executive Outlook revealed in a presentation that 75% of 280 surveyed C-suite executives across pharma and medtech expressed a positive or cautiously positive outlook. Yet beneath that headline lies a sharp transatlantic divide.

    Feb 19, 2026
  • Red Light Therapy Shows Promise for Treating Brain Injuries

    Bio-IT World | Repetitive head acceleration events (RHAEs) are repeated impacts that rapidly move the head and can cause concussions and brain damage. Yet current interventions remain reactive, focused on rest and symptom management after injury, rather than preventing microscopic damage that accumulates over time. A new study from the University of Utah Health has found an unconventional approach: photobiomodulation (PBM), or red light therapy.

    Feb 17, 2026
  • New AI Approach Weighs Data ‘Temperature’ to Improve Prediction Accuracy

    Bio-IT World | Anything that can be defined as a system—a mixed-bag list that includes physical materials like silicon and graphene as well as patient-specific implantable devices and the human brain—are subject to the law of entropy, meaning its disorder irreversibly increases over time if left alone. It turns out that this fundamental concept has a more comprehensive approach, dubbed zentropy by its creators at Penn State.

    Feb 12, 2026
  • Redefining Hypertension Treatment with Brain’s Control Circuit

    Bio-IT World | For decades, the industry’s approach to treating high blood pressure has centered on various organs—the heart, kidneys, and blood vessels. A new study suggests that this strategy may address downstream effects rather than the root cause. The primary driver of hypertension in a majority of patients may reside in the brain.

    Feb 11, 2026
  • Trends from the Trenches: What Lies Ahead in Bioinvestment

    Bio-IT World | After a turbulent few years for biotechnology, investors and entrepreneurs are recalibrating. That shift was the main topic of conversation in the most recent Trends from the Trenches episode, with John Keilty, venture partner at Third Rock Ventures, and host Eleanor Howe, founder and CEO of Diamond Age Data Science.

    Feb 10, 2026
  • The Role of the Statistical Programmer is Evolving: Here’s How It’s Changing and What That Means for Pharmaceutical Companies

    Bio-IT World | For decades, the role of statistical programmers in drug development was clearly defined. They were responsible for producing validated tables, listings, and figures from clinical trial data, most often using statistical analysis systems, within structured workflows for regulatory submissions. That model is now under pressure.

    Feb 6, 2026
  • PacBio Sells Their Short-Read IP to Illumina

    Bio-IT World | Yesterday, PacBio announced the completion of the sale of short-read DNA sequencing technology to Illumina. PacBio received $48.1 million in net cash proceeds from the transaction. The sale closed on January 30, 2026.

    Feb 3, 2026
  • Unlocking the Dangers of Disrupted Sleep

    Bio-IT World | It has been known for some time now that for people with irregular sleep patterns, including shift workers and frequent travelers across time zones, disruptions to the body’s circadian rhythm can be deadly. The dangers have notably included heightened risk of aggressive breast cancer.

    Feb 3, 2026